Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24773738 | 0.88 | NCF1 (0.40) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL12605051 | 0.88 | NCF1 (0.40) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL26845986 | 0.88 | NCF1 (0.40) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL17285887 | 0.88 | NCF1 (0.40) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL17918966 | 0.87 | GNAI3 (0.43) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL25571623 | 0.85 | NCF1 (0.43) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL2279449 | 0.83 | NCF1 (0.43) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL21271537 | 0.83 | NCF1 (0.43) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL24319846 | 0.82 | NCF1 (0.41) | NCF1GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL24319173 | 0.81 | NCF1 (0.43) | NCF1GNAI3GNAO1GNAI1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360794-A1 | JAK INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360794-A1 | JAK INHIBITOR | JAK2, JAK1, JAK3 | NCF1 863/4885GNAI3 412/4885GNAO1 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.